How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%Zacks Investment Research • 05/15/24
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/14/24
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 05/09/24
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive OfficerBusiness Wire • 03/28/24
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMOBusiness Wire • 01/08/24
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology SummitBusiness Wire • 01/03/24
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in BangkokBusiness Wire • 12/04/23
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business HighlightsBusiness Wire • 11/13/23
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research InstituteBusiness Wire • 09/12/23
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business HighlightsBusiness Wire • 08/14/23
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual AntagonistBusiness Wire • 06/06/23
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune DiseasesBusiness Wire • 04/27/23